Full Press Release Details
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration.
BIIB
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Key Takeaway: Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Price reaction · baseline $270.02 (2023-02-24 close) · clean, no other BIIB news in the window
day 0 close
-0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis